Fidelity International’s Apogee Therapeutics APGE Stock Holding History

Fidelity International’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.9K	Hold	105	–	–	﹤0.01%	1128
2026 Q1	$8.84K	Buy	+105	New	+$7.63K	﹤0.01%	1087

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Fidelity International's APGE Position: Q2 2026 in Review

Fidelity International held its Apogee Therapeutics (APGE) position steady in Q2 2026 at 105 shares worth $13.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1128.

Fidelity International first reported a position in APGE in Q1 2026 and has held it in 2 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Fidelity International held 105 shares of Apogee Therapeutics worth $13.9K as of Q2 2026.
Fidelity International left its Apogee Therapeutics share count unchanged in Q2 2026.
Apogee Therapeutics made up ﹤0.01% of Fidelity International's portfolio in Q2 2026, its #1128 holding.
Fidelity International first reported a position in Apogee Therapeutics in Q1 2026 and has held it in 2 quarters since.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Fidelity International's 13F filing for Q2 2026, filed 13 Aug 2026.